NeuroPace Overview
NeuroPace (NPCE) has a ROE of -89.35%, below the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow-89.35%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
NeuroPace (NPCE) currently reports a ROE of -89.35%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore NeuroPace's ROE history and peer comparisons.
NeuroPace's ROE of -89.35% is lower than the Healthcare sector average of 29.33%. That is roughly 404.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but NeuroPace's current -89.35% should be judged against Healthcare norms (sector average: 29.33%) and against NPCE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -89.35%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for NeuroPace, and consider following NPCE for alerts when major investors trade the stock.
NeuroPace is classified in the Healthcare sector. On ROE, it currently shows -89.35% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NPCE with unrelated industries.
